Related Experiment Videos
Thrombectomy and distal protection devices.
R Rajagopal1, C Musto, A La Manna
1Department of Cardiology, Royal Brompton Hospital, London, UK.
Minerva Cardioangiologica
|September 24, 2005
Summary
Distal embolization during angioplasty, especially in saphenous vein grafts and acute myocardial infarction, can be reduced by mechanical thrombectomy and distal protection devices. However, large trials are needed to confirm their clinical benefit and widespread use.
Area of Science:
- Interventional Cardiology
- Cardiovascular Devices
- Medical Technology
Background:
- Distal embolization is a complication of percutaneous coronary interventions (PCI), occurring in 15-20% of saphenous vein graft (SVG) angioplasties and in native artery thrombus, particularly during acute myocardial infarction (AMI).
- Mechanical thrombectomy and distal protection devices aim to mitigate this complication.
- Existing evidence for these devices in AMI is limited, with some showing promise in surrogate endpoints but lacking large randomized trials for hard clinical outcomes.
Purpose of the Study:
- To review the current status and clinical utility of mechanical thrombectomy and distal protection devices in reducing distal embolization during PCI.
- To evaluate the effectiveness of these devices in specific scenarios like SVG interventions and acute myocardial infarction.
- To discuss the potential future role of these devices in routine angioplasty procedures.
Main Methods:
- Review of existing literature on mechanical thrombectomy devices (e.g., Angiojet, X-Sizer, Excimer LASER, aspiration catheters) and distal protection devices.
- Analysis of outcomes from key randomized trials (e.g., SAFER, FIRE, EMERALD) and guidelines (e.g., ESC).
- Discussion of emerging technologies like proximal occlusion devices.
Main Results:
- Mechanical thrombectomy shows benefit in thrombus-containing lesions compared to thrombolysis, but not consistently in AMI.
- Distal protection devices are recommended for SVG treatment but showed no clinical benefit in AMI in the EMERALD trial.
- Proximal occlusion devices offer potential early protection, especially in totally occluded vessels.
Conclusions:
- While devices like distal protection are standard in SVG PCI, their benefit in AMI remains unproven by large trials.
- Miniaturized thrombectomy devices and filters show technical improvements, but their role in mainstream angioplasty is uncertain due to limited large-scale evidence.
- Further large, controlled studies are essential to determine if these devices will become standard adjuncts to PCI or remain niche applications.